Table 9.

Observed cancer cases for the MSH6 cohort with 100% or 50% probability of MMR mutation (excluding colorectal and endometrial cancer)

Primary cancer	Observed number	Proportion [%]	LL 95%	UL 95%	Proportion [%] in Sweden 1970	Proportion [%] in Sweden 2010	Reference outside CI
Breast	16	17.78	10	25.56	21.31	29.43	No
Ovary and Fallopian tube	14	15.56	8.89	23.33	6.4	2.6	above
Prostate	13	14.44	7.78	22.22	5.5	11.58	No
Kidney/urinary tract excl prostate	10	11.11	5.56	17.78	8.24	5.57	No
Stomach	8	8.89	3.33	15.56	6.74	1.38	No
Brain and nervous system	8	8.89	3.33	15.56	4.88	4.16	No
Blood and lymphatic tissue	7	7.78	2.22	13.33	8.66	8.21	No
Cervix	4	4.44	1.11	8.89	5.93	1.79	No
Liver and biliary system	3	3.33	0	7.78	3.14	1.71	No
Pancreas	2	2.22	0	5.56	3.23	1.85	No
Lung and airways	2	2.22	0	5.56	6.49	7	below
Skin excl melanom	1	1.11	0	3.33	1.96	5.44	No
Endocrine cancer	1	1.11	0	3.33	2.17	1.81	No
Bone and soft tissue	1	1.11	0	3.33	1.24	0.83	No
Head and neck	0	0	0	0	2.94	2.55	below
Oesophagus	0	0	0	0	0.75	0.54	below
Small bowel	0	0	0	0	0.5	0.56	below
female genital organ	0	0	0	0	0.72	0.46	below
Testicle	0	0	0	0	0.49	0.9	below
Penis	0	0	0	0	0.18	0.11	below
Malign melanom	0	0	0	0	3	7.23	below
Eye	0	0	0	0	0.47	0.34	below
Thyroid	0	0	0	0	1.35	1.59	below
Unspecified location	0	0	0	0	3.72	2.37	below

The observed proportions adjusted for age and sex are compared to those of the general population in year 1970 and 2010 (ref National Board of Health and Welfare). If the observed confidence interval in the Lynch syndrome group did not overlap with the proportions in the general population, the reference is denoted as “above” the reference and is marked in bold

LL Lower level of 95% confidence interval, UL upper level of 95% confidence interval